Comprehensive information about experimentally validated enhancers
| Enhancer ID: | E_01804 |
| Species: | Homo sapiens |
| Position : | chr18:48949564-48951076 |
| Year: | 2022 |
| Title: | HDAC5-mediated Smad7 silencing through MEF2A is critical for fibroblast activation and hypertrophic scar formation |
| Genome Build: | hg38 |
| Enhancer Type: | Enhancer |
| Condition: | Disease |
| Disease Name: | hepatocellular carcinoma |
| PMID: | 36263180 |
| MONDO: | MONDO:0007256 |
| Tissue: | Liver |
| Tissue Ontology ID: | UBERON:0002107 |
| Cell Source: | HuH7 cells |
| CVCL ID: | CVCL_0336 |
| Cell Type: | hepatocellular carcinoma cell |
| Cell Ontology ID: | CL:0000182 |
| Experiment Type: | Enhancer activity assay, TF binding assay |
| High Throughput Method: | |
| Low Throughput Method: | Luciferase Reporter Assay, ChIP-RT-qPCR |
| Target gene : | SMAD7 |
| TF name : | MEF2A |
| Regulatory State : | Active |
| GeneName | Pathway Name | Source | Gene Number |
|---|---|---|---|
| MEF2A | CDO in myogenesis | reactome | 29 |
| MEF2A | ERK/MAPK targets | reactome | 17 |
| MEF2A | Signaling mediated by p38-alpha and p38-beta | pid | 35 |
| MEF2A | TGF_beta_Receptor | netpath | 220 |
| MEF2A | Hs_p38_MAPK_Signaling_Pathway_WP400_72084 | wikipathways | 28 |